AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28408148
Drug: Brass wire
RxNorm normalized name: Brassica napus oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brass wire ligature treatment without mandibular third molar germectomy (group B)
Trial: 23419459
Drug: OnabotulinumtoxinA detrusor
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA detrusor injections
Trial: 23419459
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no OnabotulinumtoxinA injections)
Trial: 21233462
Drug: FAME therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAME therapy (family-mediated exercise therapy) for 8 weeks
Trial: 21233462
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy with no formal input from family members (Control)
Trial: 19436681
Drug: Losartan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (25 mg twice daily)
Trial: 15361495
Drug: Diet excluding
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet excluding all foods to which they had raised IgG antibodies
Trial: 15361495
Drug: Sham diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham diet excluding the same number of foods but not those to which they had antibodies
Trial: 7979622
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg four times a day)
Trial: 30670840
Drug: Low-intensity extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity extracorporeal shockwave therapy (Li-ESWT)
Trial: 28608496
Drug: Intravenously pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously pantoprazole 40 mg once daily
Trial: 26244837
Drug: Gentamicin solution
RxNorm normalized name: gentamicin Injectable Solution
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin solution (Group 2)
Trial: 26244837
Drug: Clindamycin solution
RxNorm normalized name: clindamycin Oral Solution
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin solution (Group 3)
Trial: 23280086
Drug: ALL‐2 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALL‐2 regimen (cytarabine 3 g/m(2) daily for 5 days with mitoxantrone 80 mg/m(2))
Trial: 23280086
Drug: L‐20 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐20 regimen (standard 4‐drug induction)
Trial: 23280086
Drug: L‐20 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐20 regimen
Trial: 9093646
Drug: Pancuronium (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.10 mg.kg‐1)
Trial: 9093646
Drug: Atracurium (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.50 mg.kg‐1)
Trial: 9093646
Drug: Atracurium (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.16 mg.kg‐1) after Pancuronium
Trial: 9093646
Drug: Pancuronium (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.03 mg.kg‐1)
Trial: 1868024
Drug: Sequential combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combination chemotherapy: cyclophosphamide, doxorubicin, 5-fluorouracil, followed by cisplatin and hexamethylmelamine
Trial: 1868024
Drug: 3-drug combination
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-drug combination alternating with the 2-drug combination every other month
Trial: 7133974
Drug: Pirprofen 400
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pirprofen 400 mg
Trial: 23265757
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of amoxycillin 1.0 g preoperatively followed by two postoperative doses of saline four hourly (single dose group)
Trial: 23265757
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of amoxycillin 1.0 g preoperatively followed by two postoperative doses of amoxycillin 0.5 g four hourly (short course group)
Trial: 20608879
Drug: Transdermal patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch with two drug-containing layers (20% and 80% concentrations) and a barrier layer (14% thickness)
Trial: 19185242
Drug: epi‐Shugarcaine solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epi‐Shugarcaine solution (epinephrine 0.025% and lidocaine 0.75% in fortified balanced salt solution [BSS Plus])
Trial: 19185242
Drug: Lundberg and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lundberg and Behndig's intracameral dilation solution (cyclopentolate 0.1%, phenylephrine 1.5%, and lidocaine 1%)
Trial: 17332444
Drug: Mental practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental practice (MP) sessions, 30 minutes, 2 days/week for 6 weeks, directly after therapy
Trial: 15026102
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus an individually tailored and administered educational intervention promoting safe-driving strategies
Trial: 10649160
Drug: Twice-weekly fetal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly fetal surveillance
Trial: 9150703
Drug: Lanreotide (LRT)
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanreotide (LRT) 0.04 g i.m. once every 2 weeks for 3 months
Trial: 9150703
Drug: Water injection
RxNorm normalized name: electroly,inj/dextrose-water INJECTION AMPUL (ML)
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water injection i.m. once every 2 weeks for 3 months (Control)
Trial: 8103874
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase (100 mg over 3 h)
Trial: 1919305
Drug: Hydroxyzine 50
RxNorm normalized name: hydroxyzine hydrochloride 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 50 mg administered 10 minutes after 5 mg epidural morphine
Trial: 30265882
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TXA) - 3 doses of 2g at 4, 10, and 16 hours postoperatively
Trial: 30265882
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) - 3 doses of 1g at 6, 12, and 18 hours postoperatively
Trial: 30265882
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral and intravenous TXA)
Trial: 20379947
Drug: Quality control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality control assessments of explanted implant failures
Trial: 18342952
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with antidepressants
Trial: 16377699
Drug: BAL8557 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL8557 (100 mg loading dose followed by 50 mg maintenance dose of BAL4815)
Trial: 16377699
Drug: BAL8557 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL8557 (200 mg loading dose followed by 100 mg maintenance dose of BAL4815)
Trial: 12729001
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture (5.6 g twice daily)
Trial: 1528643
Drug: Acellular pertussis-diphtheria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis-diphtheria tetanus toxoids vaccine (APDT)
Trial: 1528643
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell DTP vaccine
Trial: 26923773
Drug: Carprofen (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen (2.2 mg/kg per os every 12 hours for 7 days)
Trial: 26923773
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel capsule (per os every 12 hours for 7 days)
Trial: 22382633
Drug: PegIFNα‐2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα‐2a (180 μg) plus ribavirin
Trial: 22382633
Drug: PegIFNα‐2b (60-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα‐2b (60-150 μg) plus ribavirin
Trial: 22382633
Drug: PegIFNα‐2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα‐2a (180 μg) plus ribavirin in IL28B TT genotype patients
Trial: 22382633
Drug: PegIFNα‐2b (60-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα‐2b (60-150 μg) plus ribavirin in IL28B TT genotype patients
Trial: 22382633
Drug: PegIFNα‐2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα‐2a (180 μg) plus ribavirin in patients weighing <60 kg, women, and patients aged >60 years
Trial: 22382633
Drug: PegIFNα‐2b (60-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα‐2b (60-150 μg) plus ribavirin in patients weighing <60 kg, women, and patients aged >60 years
Trial: 17651479
Drug: Conventional quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional quadruple therapy (QT) - omeprazole 20 mg bid, bismuth citrate 120 mg qid, tetracycline 500 mg qid, metronidazole 500 mg tid for 7 days
Trial: 17651479
Drug: Rifabutin-based triple
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin-based triple therapy (OAR) - omeprazole 20 mg bid, amoxicillin 1 gr bid, rifabutin 150 mg bid for 7 days
Trial: 17651479
Drug: Conventional quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional quadruple therapy (QT)
Trial: 17651479
Drug: Rifabutin-based triple
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin-based triple therapy (OAR)
Trial: 16093415
Drug: Pairwise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pairwise therapy
Trial: 10442360
Drug: UFT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT plus oral calcium folinate
Trial: 7844595
Drug: High-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intramuscular ASNase (25,000 IU/m2) weekly (n = 8)
Trial: 7844595
Drug: Standard-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose intramuscular ASNase (10,000 IU/m2) every 3 days (n = 12)
Trial: 367433
Drug: Topical pindolol
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pindolol
Trial: 367433
Drug: Intravenous pindolol
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pindolol
Trial: 22745245
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg daily for 12 weeks
Trial: 26303187
Drug: Complex decongestive
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex decongestive therapy (CDT) including Vodder II Manual Lymph Drainage
Trial: 8964113
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamin C (2 g) and vitamin E (100 and 800 U)
Trial: 1803141
Drug: Endonasal calcitrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endonasal calcitrin (3 units twice a day for 1-1.5 months)
Trial: 1803141
Drug: Intramuscular calcitrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular calcitrin (not specified)
Trial: 6438672
Drug: Diazepam (10-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10-160 mg)
Trial: 6438672
Drug: Oxazepam (30-480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (30-480 mg)
Trial: 6438672
Drug: Diazepam (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (160 mg)
Trial: 29322164
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.1 mg/d) plus intermittent micronized progesterone (200 mg/d for 12 days every 3 months)
Trial: 29322164
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol plus intermittent micronized progesterone (TE+IMP)
Trial: 22103635
Drug: BCM (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCM (50mg butalbital, 325mg acetaminophen, 40mg caffeine)
Trial: 20017668
Drug: Pharmacogenomic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomic therapy
Trial: 20017668
Drug: Integration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integration of pharmacogenomic therapy into practice
Trial: 17577005
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents (8 trials, 4876 participants)
Trial: 17577005
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin (12 trials, 12,963 participants)
Trial: 17577005
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy (general)
Trial: 30987577
Drug: Postoperative urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative urinary NGAL at 48 hours >156ng/mL
Trial: 30987577
Drug: Additive EuroSCORE,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additive EuroSCORE, age, current smoking, and post-operative antibiotics usage
Trial: 23998375
Drug: rhBMP-2/ACS (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBMP-2/ACS (1.5 mg/ml)
Trial: 20082245
Drug: Combined Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Chinese drugs (Shengmai Injection by intravenous dripping and Gujin Granule by oral intake) plus Navelbine and Cisplatin (NP) chemotherapy
Trial: 20082245
Drug: Navelbine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navelbine and Cisplatin (NP) chemotherapy alone
Trial: 20082245
Drug: Combined Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Chinese drugs (Shengmai Injection and Gujin Granule) plus NP chemotherapy
Trial: 9385493
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg/d (30 patients with 37 lesions)
Trial: 9385493
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg/d (40 patients with 45 lesions)
Trial: 2688781
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pimozide and lithium
Trial: 57914
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of gamma globulin
Trial: 57914
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of gamma globulin
Trial: 30790529
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid capsules
Trial: 9709932
Drug: D‐AG (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐AG (500 mg daily)
Trial: 9709932
Drug: DL‐AG (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL‐AG (1000 mg daily)
Trial: 2228629
Drug: Special Intervention
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special Intervention (SI) for preventive therapy patients
Trial: 369921
Drug: Ciclazindol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclazindol (50 mg b.d.)
Trial: 369921
Drug: Amitriptyline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50 mg b.d.)
Trial: 11249050
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cisplatin 100 mg/m2 on day 1 and vinorelbine 30 mg/m2 on days 1, 8, 15, 22, with cycles repeated every four weeks (arm A)
Trial: 11249050
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cisplatin and vinorelbine plus early WBRT 30 Gy/10 fx/12 days (arm B)
Trial: 24760002
Drug: 7-valent conjugate
RxNorm normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent conjugate vaccine (PCV7) followed by 23-valent polysaccharide vaccine (23vPPV) 6 months later
Trial: 24760002
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide vaccine (23vPPV) alone
Trial: 22528535
Drug: hCG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG treatment on day 0, 1, and 2 (Group III)
Trial: 22528535
Drug: hCG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG treatment on days 0 and 1 (Group II)
Trial: 22528535
Drug: hCG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG treatment on day 0 (Group I)
Trial: 22528535
Drug: hCG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG treatment (all groups)
Trial: 17885008
Drug: Isoflavone-rich soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone-rich soy protein isolate (SPI+) (107 mg isoflavones/d)
Trial: 17885008
Drug: Alcohol-washed soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-washed soy protein isolate (SPI-) (<6 mg isoflavones/d)
Trial: 9465848
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg once daily, increased to 10 mg if necessary)
Trial: 2118272
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy for 4 months
Trial: 365123
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three drugs (Methylphenidate, Dextroamphetamine, Caffeine)
Trial: 25937024
Drug: 12-week non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-week non-surgical treatment program (individualized progressed neuromuscular exercise, patient education, insoles, dietary advice, prescription of pain medication if indicated)
Trial: 25937024
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (two leaflets with information and advice on knee OA and recommended treatments)
Trial: 8732377
Drug: Tissue plasminogen
RxNorm normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tissue plasminogen activator with intravenous heparin
Trial: 8732377
Drug: Streptokinase plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase plus tissue plasminogen activator with intravenous heparin
Trial: 2008949
Drug: Midazolam (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (1, 2, or 3 mg)
Trial: 2008949
Drug: Midazolam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (3 mg)
Trial: 26383577
Drug: Dental health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental health instruction before treatment
Trial: 10685653
Drug: Concurrent biochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent biochemotherapy with cisplatin, vinblastine, and dacarbazine (CVD) plus IL-2 and IFN-alpha
Trial: 7512679
Drug: Ringer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer solution without antihistamines
Trial: 7512679
Drug: Haemaccel without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haemaccel without antihistamines
Trial: 7512679
Drug: Antihistamines (dimetindene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines (dimetindene plus cimetidine)
Trial: 3343463
Drug: Sequential pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pulse defibrillation with four small mesh electrodes (6 cm2)
Trial: 3343463
Drug: Sequential pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pulse defibrillation with two small (6 cm2) and two large (13 cm2) mesh electrodes
Trial: 3343463
Drug: Sequential pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pulse defibrillation with four large mesh electrodes (13 cm2)
Trial: 25802309
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine administered to vaccine-naive children
Trial: 23810742
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) meloxicam (0.2mg/kg)
Trial: 23810742
Drug: Rectal insufflation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal insufflation of ozone (10 mL of 30 μg/mL)
Trial: 23810742
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of ozone (0.5 mL of 30 μg/mL)